ReviewEpilepsia open2022
A complex systems view on the current hypotheses of epilepsy pharmacoresistance.
Review in Epilepsia open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The efficacy and safety of third-generation antiseizure medications and non-invasive brain stimulation to treat refractory epilepsy: a systematic review and network meta-analysis study.Frontiers in neurology · 2023Pooled it
- Molecular and Functional Alterations of P-Glycoprotein in a Genetic Model of Epilepsy: Insights from the Wistar Audiogenic Rat.International journal of molecular sciences · 2026Article
- The scale for estimating prognosis of epilepsy to predict in patients with epilepsy: a 506-patient cohort study.BMC neurology · 2026Article
- Etiology, Symptoms, and Treatment of Epilepsy: Advances and Perspectives.Brain sciences · 2026Article
- New directions for complex systems in contemporary neuroscience: a morphodynamic and emergent function approach.Frontiers in computational neuroscience · 2026Review
- EEG signal dimension is an index of seizure propensity and antiseizure medication effects in a mouse model of acquired epilepsy.Epilepsia · 2025Article
- The Constrained Disorder Principle Overcomes the Challenges of Methods for Assessing Uncertainty in Biological Systems.Journal of personalized medicine · 2024Review
- Cenobamate, a New Promising Antiseizure Medication: Experimental and Clinical Aspects.International journal of molecular sciences · 2024Review
- Advancements in the application of nanotechnology for the management of epileptic seizures.Acta epileptologica · 2024Review
- Cell-specific extracellular vesicle-encapsulated exogenous GABA controls seizures in epilepsy.Stem cell research & therapy · 2024Article
- Revisiting the concept of drug-resistant epilepsy: A TASK1 report of the ILAE/AES Joint Translational Task Force.Epilepsia · 2023Article
- MicroRNA-335-5p suppresses voltage-gated sodium channel expression and may be a target for seizure control.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- A complex systems view on the current hypotheses of epilepsy pharmacoresistance.Epilepsia open · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Drug-resistant epilepsy remains to this day as a highly prevalent condition affecting around one-third of patients with epilepsy, despite all the research and the development of several new antiseizure medications (ASMs) over the last decades. Epilepsies are multifactorial complex diseases, commonly associated with psychiatric, neurological, and somatic comorbidities. Thus, to solve the puzzling problem of pharmacoresistance, the diagnosis and modeling of epilepsy and comorbidities need to change toward a complex system approach. In this review, we have summarized the sequence of events for the definition of epilepsies and comorbidities, the search for mechanisms, and the major hypotheses of pharmacoresistance, drawing attention to some of the many converging aspects between the proposed mechanisms, their supporting evidence, and comorbidities-related alterations. The use of systems biology applied to epileptology may lead to the discovery of new targets and the development of new ASMs, as may advance our understanding of the epilepsies and their comorbidities, providing much deeper insight on multidrug pharmacoresistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.